Today Integra Lifesciences Holdings (IART) Hits New Lifetime High
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.
Trade-Ideas LLC identified
(
) as a new lifetime high candidate. In addition to specific proprietary factors, Trade-Ideas identified Integra Lifesciences Holdings as such a stock due to the following factors:
- IART has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $8.6 million.
- IART has traded 1,062 shares today.
- IART is trading at a new lifetime high.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in IART with the Ticky from Trade-Ideas. See the FREE profile for IART NOW at Trade-Ideas
More details on IART:
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in five segments: U.S. Neurosurgery; U.S. Extremities; U.S. IART has a PE ratio of 58.2. Currently there are 6 analysts that rate Integra Lifesciences Holdings a buy, no analysts rate it a sell, and 7 rate it a hold.
The average volume for Integra Lifesciences Holdings has been 163,200 shares per day over the past 30 days. Integra Lifesciences has a market cap of $2.0 billion and is part of the health care sector and health services industry. The stock has a beta of 0.80 and a short float of 11.6% with 16.71 days to cover. Shares are up 12% year-to-date as of the close of trading on Thursday.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Analysis:
rates Integra Lifesciences Holdings as a
. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth, compelling growth in net income, good cash flow from operations and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.
Highlights from the ratings report include:
- The revenue growth came in higher than the industry average of 1.0%. Since the same quarter one year prior, revenues rose by 14.2%. This growth in revenue appears to have trickled down to the company's bottom line, improving the earnings per share.
- INTEGRA LIFESCIENCES HLDGS has improved earnings per share by 15.6% in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past year. We feel that this trend should continue. During the past fiscal year, INTEGRA LIFESCIENCES HLDGS turned its bottom line around by earning $1.04 versus -$0.81 in the prior year. This year, the market expects an improvement in earnings ($3.16 versus $1.04).
- The net income growth from the same quarter one year ago has exceeded that of the S&P 500 and the Health Care Equipment & Supplies industry average. The net income increased by 24.6% when compared to the same quarter one year prior, going from $13.77 million to $17.17 million.
- Net operating cash flow has significantly increased by 77.47% to $20.76 million when compared to the same quarter last year. In addition, INTEGRA LIFESCIENCES HLDGS has also vastly surpassed the industry average cash flow growth rate of -7.27%.
- The gross profit margin for INTEGRA LIFESCIENCES HLDGS is rather high; currently it is at 68.62%. It has increased from the same quarter the previous year. Despite the strong results of the gross profit margin, IART's net profit margin of 6.80% significantly trails the industry average.
- You can view the full Integra Lifesciences Holdings Ratings Report.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
null